A diagnosis of pulmonary fibrosis can feel like the ground shifting beneath your feet. It is a condition that many people have never heard of — until they are sitting in a pulmonologist's office being told they have it. The questions come quickly: What does this mean for my life? Will it get worse? What can be done?

As a pulmonologist, I want to give you honest, clear answers to those questions. Pulmonary fibrosis is a serious condition — I will not pretend otherwise. But understanding it properly, knowing what to watch for, and working closely with a specialist gives patients the best possible chance of maintaining quality of life and staying ahead of the disease.

This article covers everything you need to know: what pulmonary fibrosis actually is, what causes it, how it is diagnosed, what treatment looks like today, and how patients can live well with this condition.

What Is Pulmonary Fibrosis?

Pulmonary fibrosis is a chronic lung disease in which the tissue deep within the lungs becomes damaged and scarred over time. The word "fibrosis" simply means scarring — and in this disease, progressive scarring replaces the soft, elastic lung tissue that normally allows the lungs to expand and contract with each breath.

As scar tissue accumulates, the lungs become stiffer and thicker. They lose their ability to stretch fully, which means less air — and therefore less oxygen — reaches the bloodstream with each breath. Over time, this leads to worsening breathlessness, reduced exercise tolerance, and a persistent dry cough that does not go away.

The most common and most serious form of this condition is called Idiopathic Pulmonary Fibrosis, or IPF. "Idiopathic" means the cause cannot be identified — which is both what makes it challenging to treat and why ongoing research into its mechanisms is so important. IPF affects predominantly adults over the age of 60, and it is more common in men than women.

What Causes Pulmonary Fibrosis?

This is one of the most common questions patients ask — and one of the most difficult to answer definitively, because in many cases there is no single identifiable cause. However, there are several well-established categories.

Idiopathic (Unknown Cause)

In IPF — the most prevalent form — the precise trigger for scarring remains unknown. Researchers believe it involves a combination of genetic susceptibility and environmental exposures that cause repeated microscopic injury to the delicate cells lining the air sacs. The body attempts to repair this damage, but instead of healing normally, it lays down excessive scar tissue that permanently stiffens the lung.

Occupational and Environmental Exposures

Long-term exposure to certain dusts and particles is a well-documented cause of pulmonary fibrosis. This includes:

• Asbestos — causing asbestosis, one of the most well-known occupational lung diseases
• Silica dust — common in mining, quarrying, and construction work
• Coal dust — responsible for coal workers' pneumoconiosis
• Bird and animal drsts — prolonged exposure to feathers, droppings, or animal proteins can cause hypersensitivity pneumonitis, which may progress to fibrosis
• Agricultural dusts and molds — particularly in farming environments

Autoimmune and Connective Tissue Diseases

Pulmonary fibrosis can develop as a complication of several autoimmune conditions, including rheumatoid arthritis, systemic lupus erythematosus (SLE), scleroderma, and Sjögren's syndrome. In these cases, the immune system's attack on the body's own tissues extends to the lungs, triggering inflammation and subsequent scarring.

Medications

Certain medications are known to cause lung toxicity that can lead to fibrosis with prolonged use. These include some chemotherapy agents, amiodarone (used for heart rhythm disorders), methotrexate, and nitrofurantoin. This does not mean these medications should be avoided — they are often essential — but patients taking them should have their lung function monitored regularly.

Radiation Therapy

Radiation treatment to the chest — most commonly for breast cancer or lymphoma — can damage lung tissue in the field of treatment, occasionally leading to localised pulmonary fibrosis months or years after therapy.

Genetic Factors

A small proportion of pulmonary fibrosis cases — around 2 to 5 percent — are familial, meaning multiple members of the same family are affected. Specific gene mutations have been identified that increase susceptibility, and genetic testing is increasingly available for families where more than one member has been diagnosed.

Recognising the Symptoms

One of the most challenging aspects of pulmonary fibrosis is that its early symptoms are easy to attribute to other causes — ageing, deconditioning, or a recent respiratory illness. By the time many patients are diagnosed, the disease has already been present and progressing for months or even years.

The most common symptoms include:

• Progressive breathlessness — initially only on exertion, such as climbing stairs or walking uphill, but gradually occurring with less and less activity
• A persistent dry cough — not productive of mucus, and not relieved by cough medicines or inhalers
• Fatigue and weakness — often profound, and disproportionate to the level of activity
• Unexplained weight loss — in more advanced disease
• Aching muscles and joints — particularly in fibrosis associated with autoimmune conditions
• Clubbing of the fingers — a characteristic rounding and widening of the fingertips that occurs in some patients with chronic low oxygen levels

Doctor's note: The symptom I hear described most consistently by newly diagnosed patients is breathlessness that they had been quietly adapting to for months — taking the lift instead of stairs, stopping to rest on walks they used to complete easily. If you have been making these kinds of quiet adjustments, please do not wait any longer to get your lungs assessed.

How Is Pulmonary Fibrosis Diagnosed?

Diagnosing pulmonary fibrosis requires a combination of clinical assessment, lung function testing, and imaging. It is not a diagnosis made from a single test, and it often involves input from a multidisciplinary team including pulmonologists, radiologists, and sometimes rheumatologists or pathologists.

Pulmonary Function Tests (PFTs)

These breathing tests measure how much air the lungs can hold and how efficiently they transfer oxygen into the bloodstream. In pulmonary fibrosis, the lungs show a characteristic "restrictive" pattern — they are smaller in volume than normal and transfer oxygen less effectively. PFTs are also invaluable for tracking disease progression over time.

High-Resolution CT Scan (HRCT)

A high-resolution CT scan of the chest is the most important imaging tool in pulmonary fibrosis. It can reveal the characteristic pattern of scarring — often described as a "honeycomb" appearance in advanced disease — and help distinguish IPF from other types of fibrotic lung disease. In many cases, an experienced radiologist can confirm the diagnosis from the CT pattern alone without the need for a biopsy.

Bronchoscopy and Bronchoalveolar Lavage

A bronchoscopy involves passing a thin, flexible camera through the airways to examine them directly and collect fluid samples from deep in the lungs. This helps rule out infection, inflammation, or other conditions that can mimic pulmonary fibrosis.

Surgical Lung Biopsy

In cases where the CT appearance is not sufficiently clear-cut, a small sample of lung tissue may be needed for examination under a microscope. This is typically performed by a thoracic surgeon using a minimally invasive technique called video-assisted thoracoscopic surgery (VATS). It is not required in every patient but provides definitive diagnostic information when needed.

Blood Tests

Blood tests help rule out autoimmune causes of fibrosis and assess general health. Specific antibody tests can identify whether a connective tissue disease may be driving the lung scarring.

Treatment Options: What Is Available Today

I want to be straightforward with patients about this: there is currently no treatment that reverses established pulmonary fibrosis or regenerates scarred lung tissue. However — and this is important — there are treatments that slow the progression of the disease significantly, and a great deal has changed in the management of IPF over the past decade.

Antifibrotic Medications

Two antifibrotic drugs — pirfenidone and nintedanib — are now approved for the treatment of IPF and have transformed outcomes for many patients. Both have been shown in large clinical trials to reduce the rate of lung function decline by approximately 50 percent compared to no treatment. They do not stop the disease, but they meaningfully slow it down — and in a progressive condition, that time matters enormously.

Side effects vary between the two medications. Pirfenidone commonly causes nausea, fatigue, and skin sensitivity to sunlight. Nintedanib most commonly causes gastrointestinal symptoms, particularly diarrhoea. Most patients find that side effects settle over the first few weeks and are manageable with appropriate guidance.

Pulmonary Rehabilitation

Pulmonary rehabilitation is a structured programme combining supervised exercise, breathing techniques, education, and psychological support. It does not change the underlying disease, but consistent evidence shows it improves exercise capacity, reduces breathlessness, and significantly improves quality of life. I recommend it to virtually every patient with pulmonary fibrosis who is able to participate.

Supplemental Oxygen Therapy

As pulmonary fibrosis progresses and oxygen levels fall, supplemental oxygen becomes an important part of management. Oxygen therapy reduces breathlessness, improves exercise tolerance, protects the heart from the strain of low oxygen, and helps patients maintain activity. Many patients use it during exertion initially, and some require it continuously as the disease advances.

Treating the Underlying Cause

Where a specific cause is identified — such as an occupational exposure, a medication, or an autoimmune disease — addressing that cause is a fundamental part of management. Removing the trigger will not reverse existing scarring, but it can slow or halt further progression.

Lung Transplantation

For carefully selected patients — typically those who are younger, have no other significant medical conditions, and whose disease is progressing despite medication — lung transplantation offers the possibility of significantly extended survival and improved quality of life. It is not appropriate for everyone, and the evaluation process is thorough. However, it remains an important option that should be discussed early with patients who may be candidates.

Clinical Trials

Research into pulmonary fibrosis is advancing rapidly. Several new treatments are currently in clinical trials, targeting different mechanisms in the scarring process. I encourage eligible patients to consider participation — not only because it may offer access to promising new therapies, but because it advances the field for every patient who comes after them.

Living Well With Pulmonary Fibrosis

A diagnosis of pulmonary fibrosis changes life — but it does not end it. Many patients live for years with this condition, maintaining meaningful activity, relationships, and purpose. How well patients do is shaped significantly by how proactively they manage their condition day to day.

• Stay as active as possible — Exercise is one of the most powerful tools available. Even gentle, regular walking helps maintain lung capacity, muscle strength, and mental health. Your pulmonologist and physiotherapist can guide a safe, appropriate level of activity for your current lung function.
• Attend all follow-up appointments — Regular pulmonary function tests and clinical reviews allow your doctor to track disease progression and adjust treatment promptly. Do not skip these even when you feel stable.
• Get vaccinated — Patients with pulmonary fibrosis are at high risk of serious complications from respiratory infections. Annual influenza vaccination, pneumococcal vaccination, and COVID-19 vaccination are all strongly recommended.
• Avoid respiratory irritants — Cigarette smoke, dust, fumes, and air pollution all place additional burden on already compromised lungs. Minimising exposure is important.
• Seek psychological support — A chronic progressive illness brings real emotional weight. Anxiety and depression are common in pulmonary fibrosis patients and deserve proper attention. Psychological support, peer groups, and patient organisations all have an important role.
• Talk openly with your family — Pulmonary fibrosis affects the whole family. Open conversations about the disease, its trajectory, and advance care planning — however difficult — allow families to face the future together rather than in uncertainty.

Doctor's note: The patients I see doing best are not necessarily those with the mildest disease. They are the ones who have understood their condition, stayed engaged with their care team, kept moving, and refused to let the diagnosis define the boundaries of their life. That approach is available to every patient — regardless of where they are in their journey.

Frequently Asked Questions

Is pulmonary fibrosis the same as COPD?

No. Although both are chronic lung conditions that cause breathlessness, they are fundamentally different diseases. COPD involves damage to the airways and air sacs that causes obstruction — the lungs become over-inflated and air is trapped. Pulmonary fibrosis involves scarring that makes the lungs stiff and reduced in volume — a restrictive rather than obstructive pattern. They require different treatments and have different trajectories.

Is pulmonary fibrosis hereditary?

In most cases, pulmonary fibrosis is not directly inherited. However, a small proportion of cases — familial pulmonary fibrosis — do cluster in families, and specific genetic mutations have been identified. If two or more members of your immediate family have been diagnosed, genetic counselling and testing is worth discussing with your pulmonologist.

Can pulmonary fibrosis be caused by smoking?

Smoking is a recognised risk factor for IPF. Current and former smokers are significantly more likely to develop IPF than non-smokers. While smoking does not cause pulmonary fibrosis in the same direct way it causes lung cancer or COPD, it appears to contribute to the repeated lung injury that may trigger the scarring process in susceptible individuals. Stopping smoking is important for every patient with pulmonary fibrosis, regardless of disease stage.

How quickly does pulmonary fibrosis progress?

This varies considerably between patients and is genuinely difficult to predict at diagnosis. Some patients experience a slow, gradual decline over many years. Others follow a more rapid course. A small number experience acute exacerbations — sudden, significant deteriorations — that can be life-threatening. Regular monitoring of lung function allows your doctor to identify any acceleration in decline and respond accordingly.

Should I tell my employer about my diagnosis?

This is a personal decision and will depend on your job, the demands it places on your breathing, and your relationship with your employer. In roles involving occupational dust or fume exposure, removing yourself from that environment is medically important, which will necessitate some disclosure. For many other roles, there is no medical reason you cannot continue working — at least in the early stages of the disease — and disclosure remains your choice. An occupational health physician can provide guidance specific to your situation.

A Final Word

I know that reading about pulmonary fibrosis — whether you have just been diagnosed, are waiting for results, or are supporting someone you love — is not easy. It is a condition that asks a great deal of patients and families alike.

What I want you to take from this article is that you are not without options, and you are not alone. The landscape of pulmonary fibrosis treatment has changed significantly in recent years, and research continues at pace. Patients who engage early with specialist care, take their medication consistently, stay as active as possible, and lean on the support available to them do meaningfully better.

If you have symptoms that concern you, a recent diagnosis you want to discuss in depth, or questions about whether your current management is optimised — please book a consultation. A thorough, specialist review can make a real difference to the path ahead.

This article is intended for general informational and educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional regarding your individual circumstances. Dr. Nabila Zaheer is a board-certified pulmonologist accepting new patients — book an appointment here.